Mimedx (MDXG) Current Deferred Revenue (2011 - 2012)

Mimedx (MDXG) posted Current Deferred Revenue of $6620.0 for Q1 2012, little changed sequentially from $6620.0 in Q4 2011.

Mimedx (MDXG) Current Deferred Revenue (2011 - 2012) Analysis & Trends

Mimedx has reported Current Deferred Revenue for 2 years, with the latest figure at $6620.0 in Q1 2012.

Quarterly Current Deferred Revenue changed N/A year-over-year to $6620.0 in Q1 2012, while the trailing twelve-month figure through Mar 2012 was $6620.0 (changed N/A YoY) and the FY2011 annual result came in at $6620.0, changed N/A from the prior year.
Current Deferred Revenue was little changed at $6620.0 in Q1 2012 per MDXG's latest filing, from $6620.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $6620.0 in Q2 2011 and troughed at $6620.0 in Q2 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn

Download Data